Silo Pharma, Inc.
SILO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001514183
No open-market purchases or sales by Silo Pharma, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q3 2026, worth $451.7K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:24 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $4.23M (5863.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Revenue | $72.1K | $72.1K | $72.1K | $72.6K | – |
| Cost of revenue | $44.3K | $5.84K | $5.84K | $5.84K | $5.00K |
| Gross profit | $27.8K | $66.3K | $66.3K | $66.3K | $66.3K |
| Operating expenses | $4.31M | $4.77M | $3.92M | $3.69M | $2.81M |
| Research and development | $2.16M | $2.37M | $845.1K | $1.29M | $693.9K |
| Selling, general and administrative | – | – | $390.1K | $227.3K | $163.0K |
| Operating income | -$4.28M | -$4.71M | -$3.86M | -$3.63M | -$2.74M |
| Interest expense | – | – | $4.87K | $2.20K | $54 |
| Income tax | – | – | – | – | $24.9K |
| Net income | -$4.23M | -$4.39M | -$3.70M | -$3.91M | $3.90M |
| EPS, basic | $-0.50 | $-1.19 | – | – | $0.04 |
| EPS, diluted | $-0.50 | $-1.19 | – | – | $0.04 |
| Weighted shares, basic | 8.38M | 3.68M | 3.08M | 2.28M | 94.9M |
| Weighted shares, diluted | 8.38M | 3.68M | 3.08M | 2.28M | 95.9M |
| Margins and growth | |||||
| Gross margin | 38.6% | 91.9% | 91.9% | 91.2% | – |
| Operating margin | -5937.0% | -6526.4% | -5347.4% | -4994.2% | – |
| Net margin | -5863.5% | -6092.6% | -5132.6% | -5380.9% | – |
| Revenue growth, year over year | 0.0% | 0.0% | −0.7% | – | – |
| Net income growth, year over year | – | – | – | −200.1% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | $4.75M | $3.91M | $3.52M | $11.4M | $9.84M |
| Short-term investments | $2.11M | $3.17M | $4.14M | – | – |
| Total current assets | $7.39M | $7.11M | $7.68M | $11.6M | $10.4M |
| Intangible assets | $217.4K | $241.2K | – | – | – |
| Total assets | $7.61M | $7.41M | $7.75M | $11.6M | $10.5M |
| Total current liabilities | $650.2K | $1.66M | $775.6K | $436.3K | $490.0K |
| Total liabilities | $1.30M | $2.38M | $1.57M | $1.30M | $1.43M |
| Shareholders' equity | $6.31M | $5.03M | $6.18M | $10.3M | $9.06M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$4.66M | -$3.83M | -$3.22M | -$3.50M | -$2.28M |
| Stock-based compensation | $117.0K | $906.8K | $871.6K | $577.7K | $395.1K |
| Investing cash flow | $644.0K | $973.8K | -$4.15M | $86.7K | $7.19M |
| Financing cash flow | $4.86M | $3.24M | -$471.1K | $4.94M | $3.79M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 162.3% | 1257.6% | 1208.9% | 795.3% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 13, 2026 | 2.16M | −83.8% | SEC |
| Aug 13, 2026 | 1.59M | −83.1% | SEC |
| May 13, 2026 | 16.3M | +262.7% | SEC |
| Mar 27, 2026 | 14.2M | +215.9% | SEC |
| Nov 13, 2025 | 13.3M | +197.0% | SEC |
| Aug 13, 2025 | 9.40M | +109.6% | SEC |
| May 8, 2025 | 4.48M | +60.0% | SEC |
| Mar 26, 2025 | 4.48M | +57.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.